Asimadoline - Tioga Pharmaceuticals

Drug Profile

Asimadoline - Tioga Pharmaceuticals

Alternative Names: EMD-61753; EMR 63 320; ONO-3951

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Ono Pharmaceutical; Tioga Pharmaceuticals
  • Class Acetamides; Opioid analgesics; Pyrrolidines; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pruritus
  • Discontinued Irritable bowel syndrome; Pain; Postoperative ileus

Most Recent Events

  • 04 Dec 2017 Safety and efficacy data from a phase II clinical trial in Pruritus released by Tioga Pharmaceuticals
  • 06 Aug 2015 Discontinued - Phase-III for Irritable bowel syndrome in USA (PO)
  • 01 Jun 2015 Phase-II clinical trials in Pruritus (In adults, In the elderly) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top